Australian biotech market today 08.04.09
Wednesday, 08 April, 2009
The pharma and biotech index is down one per cent at 3pm today, in line with the rest of the All Ordinaries.
The Big Three – Cochlear (ASX:COH), CSL (ASX:CSL) and ResMed (ASX:RMD) – have followed the rest of the index and are down on today’s trading.
Pharmaxis (ASX:PXS), which yesterday appointed US-based life science investment manager Richard van den Broek to its board, is up 8c to almost $2.
Novogen (ASX:NRT) is also up again today on very small volumes. The company today announced good results from a Phase II trial being carried out by one of its US subsidiaries, Glycotex, in wound healing. While this trial is in a cosmetic application, the company is also investigating its compound GLYC-101 in burns, surgical wounds and venous and diabetic ulcers.
Progen (ASX:PGL) is up again despite its recent dramas, settling at just over 90c today.
API manufacturer IDT Australia (ASX:IDT) is down 6c to $1.52, while Circadian (ASX:CIR) is up 3c and Clinuvel (ASX:CLV) is up 1c.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
